Trends over time in the proportion of sequential treatment and overall survival in patients with metastatic urothelial carcinoma in real-world practice.

Authors

Shoma Yamamoto

Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan

Shoma Yamamoto , MInoru Kato , Taisuke Matsue , Nao Yukimatsu , Yuji Takeyama , Taiyo Otoshi , Takeshi Yamasaki , Katsuyuki Kuratsukuri , Junji Uchida

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 606)

DOI

10.1200/JCO.2024.42.4_suppl.606

Abstract #

606

Poster Bd #

G12

Abstract Disclosures

FEATURED

Trends over time in the proportion of sequential treatment and overall survival in patients with metastatic urothelial carcinoma in real-world practice.

Authors

Shoma Yamamoto

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Evolving treatment landscape in metastatic urothelial carcinoma (mUC) post-avelumab maintenance approval: Real-world insights from The US Oncology Network.

Poster

US real-world first-line (1L) treatment patterns and outcomes for patients with metastatic urothelial carcinoma (mUC) following maintenance avelumab approval.

Poster

Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who receive second-line immunotherapy.

Poster

Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC).